| Abstract |
【Abstract】 Objective: To explore the effectiveness of augmentative magnesium valproate treatment for residual schizophrenia（RS） patients. Methods: Ninety RS patients were randomly assigned to experimental group (treated with atypical antipsychotics (AAs) in combination with magnesium valproate) and control group (treated with AAs only). Both groups were treated for 12 weeks and patients were assessed at baseline, end of week 4, week 8, and week 12 for symptom severity (assessed by Positive and Negative Symptoms Scale (PANSS) and Clinical Global Impression (CGI)), cognitive function (assessed by Treatment Emergent Symptom Scale (TESS), and Wechsler Adult Intelligence Test (WAIS), and Wechsler Memory Test (WMS)) and adverse effect (assessed by Treatment Emergent Symptom Scale (TESS)). Results: At the end of week 4, both groups exhibited significantly decreased PANSS scores (p<0.05) and experimental group showed significantly lower Positive Symptoms scores than control group (p<0.05). PANSS scores in experimental group were significantly lower than those in control group at the end of week 8 (p<0.05) and week 12 (p<0.01), The WAIS total score, verbal subscale score, operation subscale score were significantly increased in both groups at the end of week 4 (p<0.05 or p<0.01). At the end of week 8 and week 12, both groups demonstrated significantly increased WAIS total score, verbal subscale score, operation subscale score, and WMS score as compared with baseline (p<0.05 or p<0.01), while the experimental group showed greater improvement than control group (p<0.05 or p<0.01). With treatment, both groups showed a downward trend in CGI scores, while the experimental group exhibited significantly lower CGI scores than control group (p<0.01). Conclusion: AAs in combination with magnesium valproate may be more effective in improving clinic symptoms and cognitive function in patients with RS than AAs alone. Quicker control of positive symptoms with rare adverse symptoms may be achieved in AAs in combination with magnesium valproate as compared with AAs alone.
|